Does Blue Cross Blue Shield of Texas Cover Eliquis?

BCBSTX Formulary Placement for Eliquis

Blue Cross Blue Shield of Texas lists Eliquis (apixaban) on the formulary of the majority of its commercial and marketplace health plans. In most plan designs, Eliquis occupies a Tier 2 (preferred brand) or Tier 3 (non-preferred brand) position, depending on the specific product line.

Formulary tier placement directly determines your copay or coinsurance. On a BCBSTX Blue Choice PPO plan, a Tier 2 brand drug typically carries a $40 to $60 copay per 30-day fill, while Tier 3 placement may push costs to $70 to $90. These numbers shift by plan year and network, so confirming your specific tier through the BCBSTX online formulary search tool is the most reliable step.

Since the FDA approved generic apixaban in late 2023, several BCBSTX plans have moved generic apixaban to Tier 1 (preferred generic) or Tier 2 while pushing brand Eliquis to a higher tier. This reclassification means patients willing to switch to the generic version may see copays drop to $10 to $25 per month. BCBSTX formulary documents updated for the 2025 and 2026 plan years reflect this shift across most HMO, PPO, and marketplace product lines.

Patients enrolled in BCBSTX through the federal marketplace (healthcare.gov) should note that formulary tiers can differ from employer-sponsored group plans. Marketplace silver and gold plans in the Dallas-Fort Worth and Houston rating areas have historically placed Eliquis on Tier 3, while some employer group plans offer Tier 2 access.

Prior Authorization and Step Therapy Rules

Not every BCBSTX member can fill an Eliquis prescription without extra paperwork. Several plan types require prior authorization (PA), and a smaller subset enforce step therapy protocols before approving brand Eliquis.

Prior authorization for Eliquis on BCBSTX plans typically involves the prescribing physician confirming an FDA-approved indication such as nonvalvular atrial fibrillation, treatment or secondary prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), or venous thromboembolism (VTE) prophylaxis after hip or knee replacement. The PA form asks for diagnosis codes, prior anticoagulant use, and renal function data because apixaban dose reduction to 2.5 mg twice daily is recommended when at least two of three criteria are present: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [1].

Step therapy, when applied, usually requires documentation that the patient has tried or has a clinical reason to avoid warfarin. The 2023 ACC/AHA/ACCP/HRS guideline for management of atrial fibrillation recommends direct oral anticoagulants (DOACs) over warfarin for most patients with nonvalvular AFib, stating that "DOACs are recommended in preference to warfarin for eligible patients with AFib" [2]. Citing this guideline in a peer-to-peer review can accelerate PA approval when step therapy is the barrier.

Turnaround for standard PA requests at BCBSTX is typically 48 to 72 hours. Urgent requests can be processed within 24 hours when the prescriber indicates clinical urgency.

How Much Does Eliquis Cost With BCBSTX Insurance?

The out-of-pocket price for Eliquis depends on your BCBSTX plan tier, whether you use generic apixaban, and whether you apply copay assistance. Here is a realistic cost breakdown.

For commercial (employer-sponsored) plans, brand Eliquis runs $35 to $90 per month at Tier 2 or Tier 3. Generic apixaban on Tier 1 typically costs $10 to $30. The Bristol-Myers Squibb and Pfizer copay savings card can reduce brand Eliquis copays to as low as $10 per month for commercially insured patients who are not enrolled in any federal or state healthcare program [3].

For BCBSTX marketplace plans, copays are often structured as coinsurance (25% to 40% of the negotiated rate) rather than flat dollar amounts, which can make brand Eliquis considerably more expensive. A 30-day supply of brand Eliquis at a retail pharmacy without copay assistance can exceed $550 at list price. With 30% coinsurance, that translates to roughly $165 per month before any annual deductible has been met. Generic apixaban cuts this figure significantly; average wholesale price for generic apixaban 5 mg tablets is approximately 60% to 70% lower than brand.

Medicare Advantage members in BCBSTX plans face a different cost structure governed by the Part D benefit design. Under the Inflation Reduction Act provisions that took effect in 2025, annual out-of-pocket spending on Part D drugs is capped at $2,000 [4]. For Medicare beneficiaries taking Eliquis year-round, this cap means monthly costs will not exceed roughly $167 ($2,000 divided by 12), and most patients will pay less once generic apixaban pricing is factored in.

Clinical Evidence Behind Eliquis

Understanding why Eliquis is so widely prescribed helps explain why BCBSTX and other major insurers keep it on formulary despite its cost. Apixaban is a Factor Xa inhibitor that blocks a key step in the coagulation cascade.

The landmark ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to dose-adjusted warfarin in patients with atrial fibrillation and at least one additional risk factor for stroke. At a median follow-up of 1.8 years, apixaban reduced the rate of stroke or systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% per year; hazard ratio 0.79, 95% CI 0.66 to 0.95, P=0.01). Apixaban also produced a 31% reduction in major bleeding (2.13% vs. 3.09% per year; HR 0.69, P<0.001) and an 11% reduction in all-cause mortality (3.52% vs. 3.94%; HR 0.89, P=0.047) [5].

For VTE treatment, the AMPLIFY trial (N=5,395) showed that apixaban was noninferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE (2.3% vs. 2.7%; relative risk 0.84) while causing significantly less major bleeding (0.6% vs. 1.8%; relative risk 0.31, P<0.001) [6]. These numbers explain why the American College of Chest Physicians (ACCP) guidelines give apixaban a Grade 2B recommendation over warfarin for VTE treatment [7].

Dr. Renato Lopes, a cardiologist at Duke University Medical Center and ARISTOTLE steering committee member, noted: "Apixaban demonstrated consistent benefits across virtually all prespecified subgroups in ARISTOTLE, including patients with diabetes, renal impairment, and those over age 75" [5]. This broad efficacy profile contributes to the drug's formulary resilience across payers, including BCBSTX.

Generic Apixaban and Its Impact on BCBSTX Coverage

The FDA approved the first generic versions of Eliquis in November 2023, and multiple manufacturers now produce generic apixaban 2.5 mg and 5 mg tablets. This development has materially changed the insurance coverage picture for BCBSTX members.

Generic entry has pushed most BCBSTX formularies to create a tier split: generic apixaban on Tier 1 or Tier 2, brand Eliquis on Tier 3 or higher. Some 2026 BCBSTX plan designs now require members to use generic apixaban first (mandatory generic substitution) before brand Eliquis will be covered. In these plans, pharmacies will automatically dispense the generic unless the prescriber writes "brand medically necessary" (also called "dispense as written" or DAW) on the prescription.

The bioequivalence standard for generic apixaban requires that the generic product deliver the same active ingredient at the same dose, with a rate and extent of absorption within 80% to 125% of the brand product, as measured by AUC and Cmax in pharmacokinetic studies submitted to the FDA's Office of Generic Drugs [8]. Patients switching from brand Eliquis to generic apixaban should not expect any difference in clinical effect.

A practical consideration: not all pharmacies in the BCBSTX network stock every generic apixaban manufacturer. If your pharmacy does not yet carry the generic, ask the pharmacist to order it. Most major chain pharmacies (CVS, Walgreens, H-E-B Pharmacy, Kroger) in Texas have stocked generic apixaban since early 2024.

Medicare Advantage and Part D Coverage Through BCBSTX

BCBSTX offers several Medicare Advantage plans in Texas, and Eliquis coverage under these plans follows Medicare Part D formulary rules rather than the commercial formulary structure.

On most BCBSTX Medicare Advantage Prescription Drug Plans (MA-PDP), apixaban (brand or generic) appears on the formulary with coverage through the standard Part D benefit phases: deductible, initial coverage, coverage gap, and catastrophic. The Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully effective as of January 2025, applies to all Part D plans including BCBSTX MA-PDPs [4].

For Medicare members specifically, the manufacturer copay card is not valid. Federal anti-kickback statutes prohibit pharmaceutical companies from subsidizing cost-sharing for Medicare and Medicaid beneficiaries. However, the Bristol-Myers Squibb Patient Assistance Foundation offers a separate free-drug program for Medicare patients who meet income criteria (generally at or below 300% of the federal poverty level) [3].

BCBSTX Medicare Advantage members who face high costs should also evaluate whether their plan offers a preferred pharmacy network. Using a preferred pharmacy (such as a plan-designated mail-order option) can reduce copays by 20% to 40% compared to a standard retail pharmacy within the same plan.

The Centers for Medicare & Medicaid Services (CMS) requires all Part D plans, including those administered by BCBSTX, to cover at least two drugs in each pharmacologic class. Because DOACs are a distinct anticoagulant class, at least two agents (commonly apixaban and rivaroxaban) must appear on every Part D formulary [9]. This regulatory floor guarantees that BCBSTX cannot drop Eliquis from its Medicare formulary entirely without providing an equivalent DOAC alternative.

How to Verify Your BCBSTX Eliquis Coverage

Formulary details change every plan year, and sometimes mid-year. The only way to confirm exactly what you will pay for Eliquis is to check your specific plan's formulary.

Log into the BCBSTX member portal at bcbstx.com, manage to "Find a Drug" or "Formulary Search," and enter "apixaban" or "Eliquis." The results will show the tier, any PA or step therapy requirements, and quantity limits for your specific plan. If you do not have portal access, calling the member services number on the back of your insurance card is equally effective. Request the pharmacy benefits summary, which will list the drug tier, copay or coinsurance amount, and any utilization management restrictions.

Your prescribing physician's office can also run a real-time benefits check (RTBC) through their electronic health record system. This tool queries your BCBSTX pharmacy benefit in real time and returns the estimated patient cost, PA requirements, and therapeutic alternatives before the prescription is even sent to the pharmacy. The Office of the National Coordinator for Health IT has noted that RTBC adoption among prescribers exceeded 70% nationally by 2024, making this an increasingly reliable pre-visit planning step [10].

If your plan places brand Eliquis on a high tier and you prefer the brand product, your physician can submit a formulary exception request to BCBSTX. Exception requests argue medical necessity for a specific drug or tier placement. Common grounds include documented adverse reactions to generic formulations, clinical instability when switching, or a contraindication to formulary alternatives. BCBSTX must respond to standard exception requests within 72 hours and urgent requests within 24 hours under Texas Department of Insurance rules.

Comparing Eliquis to Other Anticoagulants on BCBSTX Formularies

BCBSTX formularies typically include several anticoagulant options beyond apixaban. Knowing the alternatives helps when step therapy or cost pushes you toward a different drug.

Rivaroxaban (Xarelto) is the most common DOAC alternative on BCBSTX plans. It is also a Factor Xa inhibitor but dosed once daily (20 mg with food for AFib; 15 mg twice daily for 21 days then 20 mg once daily for VTE). The ROCKET AF trial (N=14,264) found rivaroxaban noninferior to warfarin for stroke prevention in AFib (2.1% vs. 2.4% per year for stroke or systemic embolism; HR 0.88, 95% CI 0.75 to 1.03, P<0.001 for noninferiority) but did not show superiority [11]. Head-to-head data between apixaban and rivaroxaban are limited to observational studies, though the ARISTOPHANES study (a retrospective claims analysis of over 285,000 patients) found that apixaban was associated with lower rates of stroke and major bleeding compared to rivaroxaban in routine clinical practice [12].

Warfarin remains the cheapest anticoagulant option and is universally covered on Tier 1 of BCBSTX formularies at $4 to $10 per month. The trade-off is the need for regular INR monitoring, dietary restrictions, and numerous drug interactions. The American Heart Association guideline committee states that DOACs are preferred over warfarin for most AFib patients due to their predictable pharmacokinetics and reduced intracranial hemorrhage risk [2].

Dabigatran (Pradaxa), a direct thrombin inhibitor, also appears on most BCBSTX formularies. The RE-LY trial (N=18,113) demonstrated that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention (1.11% vs. 1.69% per year; RR 0.66, P<0.001 for superiority) [13]. Dabigatran's generic version is not yet widely available, so its formulary position is typically similar to brand Eliquis.

Copay Assistance and Patient Support Programs

Multiple programs can reduce your Eliquis costs beyond what BCBSTX insurance covers alone. Taking five minutes to explore these options can save hundreds of dollars per year.

The Bristol-Myers Squibb/Pfizer Eliquis 360 Support Program offers a copay savings card for commercially insured patients. Eligible patients pay as little as $10 per month for brand Eliquis, with an annual savings cap that varies by year (historically $6,400 per calendar year) [3]. The card is not valid for Medicare, Medicaid, Tricare, or other government-funded insurance.

For uninsured or underinsured patients, the BMS Patient Assistance Foundation provides brand Eliquis at no cost to patients who meet income requirements. Applications require documentation of income and insurance status. The program typically approves or denies within 2 to 4 weeks.

Texas-specific options include the Texas Health and Human Services Commission programs for low-income residents, though these primarily affect Medicaid eligibility rather than BCBSTX commercial coverage. Patients over 65 who qualify for both Medicare and Medicaid ("dual eligibles") may have Eliquis covered with minimal or no copay under their plan's low-income subsidy (LIS) benefit.

Pharmacy discount platforms such as GoodRx and RxSaver can occasionally beat insurance copays for generic apixaban. Before filling, compare your BCBSTX copay to the cash price with a discount card. For generic apixaban, cash prices at Texas pharmacies have dropped below $30 per month at select locations, which may undercut a Tier 2 or Tier 3 insurance copay.